Chapter 1. Executive summary 1.1. Market scope and segmentation 1.2. Key questions answered 1.3. Executive summary Chapter 2: Global multiplex biomarker imaging market - overview 2.1. Global market overview - historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), geography-wise market revenue (USD Mn), and market attractiveness analysis 2.2. Global market drivers 2.3. Global market challenges 2.4. Global market trends 2.5. Value chain analysis 2.6. Porter's five forces analysis 2.7. Market segmentation based on technique (immunohistochemistry [IHC], fluorescent in the situ hybridization [FISH], immunofluorescence [IF], tissue microarray [TMA], toponome imaging system [TIS]) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key market observations 2.8. Market segmentation based on component (instrument, reagents and kits, software) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations 2.9. Market segmentation based on application (oncology studies, drug safety, genetic characterization and others [neurodegeneration, protein research]) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations 2.10. Market segmentation based on end user (research institutes, translational labs, pharma and biopharma companies) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations Chapter 3: North America multiplex biomarker imaging market 3.1. Regional market overview – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key market observations 3.2. Market segmentation based on technique (immunohistochemistry [IHC], fluorescent in the situ hybridization [FISH], immunofluorescence [IF], tissue microarray [TMA], toponome imaging system [TIS]) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key market observations 3.3. Market segmentation based on component (instrument, reagents and kits, software) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations 3.4. Market segmentation based on application (oncology studies, drug safety, genetic characterization and others [neurodegeneration, protein research]) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations 3.5. Market segmentation based on end user (research institutes, translational labs, pharma and biopharma companies) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations Chapter 4: Europe multiplex biomarker imaging market 4.1. Regional market overview – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key market observations 4.2. Market segmentation based on technique (immunohistochemistry [IHC], fluorescent in the situ hybridization [FISH], immunofluorescence [IF], tissue microarray [TMA], toponome imaging system [TIS]) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key market observations 4.3. Market segmentation based on component (instrument, reagents and kits, software) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations 4.4. Market segmentation based on application (oncology studies, drug safety, genetic characterization and others [neurodegeneration, protein research]) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations 4.5. Market segmentation based on end user (research institutes, translational labs, pharma and biopharma companies) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations Chapter 5: Asia-Pacific multiplex biomarker imaging market 5.1. Regional market overview – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key market observations 5.2. Market segmentation based on technique (immunohistochemistry [IHC], fluorescent in the situ hybridization [FISH], immunofluorescence [IF], tissue microarray [TMA], toponome imaging system [TIS]) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key market observations 5.3. Market segmentation based on component (instrument, reagents and kits, software) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations 5.4. Market segmentation based on application (oncology studies, drug safety, genetic characterization and others [neurodegeneration, protein research]) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations 5.5. Market segmentation based on end user (research institutes, translational labs, pharma and biopharma companies) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations Chapter 6: Latin America multiplex biomarker imaging market 6.1. Regional market overview – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key market observations 6.2. Market segmentation based on technique (immunohistochemistry [IHC], fluorescent in the situ hybridization [FISH], immunofluorescence [IF], tissue microarray [TMA], toponome imaging system [TIS]) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key market observations 6.3. Market segmentation based on component (instrument, reagents and kits, software) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations 6.4. Market segmentation based on application (oncology studies, drug safety, genetic characterization and others [neurodegeneration, protein research]) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations 6.5. Market segmentation based on end user (research institutes, translational labs, pharma and biopharma companies) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations Chapter 7: The Middle East and Africa multiplex biomarker imaging market 7.1. Regional market overview – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key market observations 7.2. Market segmentation based on technique (immunohistochemistry [IHC], fluorescent in the situ hybridization [FISH], immunofluorescence [IF], tissue microarray [TMA], toponome imaging system [TIS]) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key market observations 7.3. Market segmentation based on component (instrument, reagents and kits, software) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations 7.4. Market segmentation based on application (oncology studies, drug safety, genetic characterization and others [neurodegeneration, protein research]) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations 7.5. Market segmentation based on end user (research institutes, translational labs, pharma and biopharma companies) – historical (2015–2017) and forecasted (2018–2023) market size (USD Mn), and key observations Chapter 8: Competitive landscape 8.1. Thermo Fisher Scientific, Inc. 8.1.a. Company snapshot 8.1.b. Product offerings 8.1.c. Growth strategies 8.1.d. Initiatives 8.1.e. Geographical presence 8.1.f. Key numbers 8.2. Perkin Elmer, Inc. 8.2.a. Company snapshot 8.2.b. Product offerings 8.2.c. Growth strategies 8.2.d. Initiatives 8.2.e. Geographical presence 8.2.f. Key numbers 8.3. Abcam Plc. 8.3.a. Company snapshot 8.3.b. Product offerings 8.3.c. Growth strategies 8.3.d. Initiatives 8.3.e. Geographical presence 8.3.f. Key numbers 8.4. Bio-Rad Laboratories Inc. 8.4.a. Company snapshot 8.4.b. Product offerings 8.4.c. Growth strategies 8.4.d. Initiatives 8.4.e. Geographical presence 8.4.f. Key numbers 8.5. U.S. Biomax, Inc. 8.5.a. Company snapshot 8.5.b. Product offerings 8.5.c. Growth strategies 8.5.d. Initiatives 8.5.e. Geographical presence 8.5.f. Key numbers 8.6. Merck KGaA 8.6.a. Company snapshot 8.6.b. Product offerings 8.6.c. Growth strategies 8.6.d. Initiatives 8.6.e. Geographical presence 8.6.f. Key numbers 8.7. Ventana Medical Systems, Inc. 8.7.a. Company snapshot 8.7.b. Product offerings 8.7.c. Growth strategies 8.7.d. Initiatives 8.7.e. Geographical presence 8.7.f. Key numbers 8.8. MicroConstants, Inc. 8.8.a. Company snapshot 8.8.b. Product offerings 8.8.c. Growth strategies 8.8.d. Initiatives 8.8.e. Geographical presence 8.8.f. Key numbers 8.9. Leica Biosystems Nussloch GmbH 8.9.a. Company snapshot 8.9.b. Product offerings 8.9.c. Growth strategies 8.9.d. Initiatives 8.9.e. Geographical presence 8.9.f. Key numbers 8.10. ToposNomos Ltd. 8.10.a. Company snapshot 8.10.b. Product offerings 8.10.c. Growth strategies 8.10.d. Initiatives 8.10.e. Geographical presence 8.10.f. Key numbers 8.11. Illumina, Inc. 8.11.a. Company snapshot 8.11.b. Product offerings 8.11.c. Growth strategies 8.11.d. Initiatives 8.11.e. Geographical presence 8.11.f. Key numbers Chapter 9: Conclusion 9.1. Future Outlook Appendix o List of tables o Research methodology o Assumptions o About Netscribes, Inc.

1. Thermo Fisher Scientific, Inc. 2. Perkin Elmer, Inc. 3. Abcam Plc. 4. Bio-Rad Laboratories Inc. 5. U.S. Biomax Inc. 6. Merck KGaA 7. Ventana Medical Systems, Inc. 8. MicroConstants, Inc 9. Leica Biosystems Nussloch GmbH 10. ToposNomos Ltd. 11. Illumina, Inc.